Status Epilepticus Population Study (STEPS)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Epileptic Seizures
- Sponsor
- University Hospital, Basel, Switzerland
- Enrollment
- 1000
- Locations
- 2
- Primary Endpoint
- Demographics
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
The aim of this observational multicenter cohort study is to gain a deeper understanding regarding the effects of treatment adaption based on information from outcome prediction models, risk stratification, as well as treatment monitoring, detection, prevention, and management of complications on course and outcome of adult patients with status epilepticus (SE).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adult patients (i.e., patients ≥18 years of age) with diagnosed SE between 2005 and 2023 who have been treated at the University Hospital of Basel or the Cantonal Hospital Aarau.
Exclusion Criteria
- •Patients younger than 18 years.
- •Patients with repetitive epileptic seizures not qualifying for SE.
- •Patients with documented refusal of the general consent.
Outcomes
Primary Outcomes
Demographics
Time Frame: between 01.01.2005 and 31.12.2023
age, sex
Seizure history and etiology
Time Frame: between 01.01.2005 and 31.12.2023
withdrawal from anti seizure drugs, structural, infectious, or autoimmune causes
Data from acute prehospital management by the emergency medical services (EMS)
Time Frame: between 01.01.2005 and 31.12.2023
extracted from the treatment protocols of the EMS
Duration of ICU (intensive care unit) and hospital stay, and destination at discharge
Time Frame: between 01.01.2005 and 31.12.2023
Duration of ICU (intensive care unit) and hospital stay, and destination at discharge
Date(s) of seizure(s) captured by electroencephalographic (EEG) data
Time Frame: between 01.01.2005 and 31.12.2023
Date(s) of seizure(s) captured by EEG
Number and Duration of SE episodes
Time Frame: between 01.01.2005 and 31.12.2023
Number and Duration (time) of SE episodes
Types of SE
Time Frame: between 01.01.2005 and 31.12.2023
Types of SE according to the current guidelines from the International League of Epilepsy (ILAE) (i.e., nonconvulsive with coma, SE with motor symptoms, focal nonconvulsive SE without coma, and subtle SE
Additional features of the seizure
Time Frame: between 01.01.2005 and 31.12.2023
length, level of consciousness at onset, previous epileptic seizures
Clinical neurologic monitoring scores
Time Frame: between 01.01.2005 and 31.12.2023
Clinical neurologic monitoring scores (e.g., Richmond Agitation-Sedation Scale (RASS) , Seda-tion-Agitation Scale (SAS), Glasgow Coma Score (GCS), Intensive Care Delirium Screening Checklist (ICDSC), Status Epilepticus Severity Score (STESS))
Laboratory parameters
Time Frame: between 01.01.2005 and 31.12.2023
C-Reactive Protein (CRP), albumin, Lactate Dehydrogenase (LDH), Creatin-Kinase (CK), procalcitonin, white blood cell levels, creatinine, liver enzymes, blood gas analyses, metabolic data
Therapeutic features
Time Frame: between 01.01.2005 and 31.12.2023
duration, dosage and number of treatment medication, number of antiseizure drugs, invasive procedures, such as intubation, mechanical, ventilation, vasopressors, installation of central lines, nutrition
Monitoring of vital signs
Time Frame: between 01.01.2005 and 31.12.2023
blood pressure, heart rate, respiratory rate, oxygen saturation of the blood, body temperature, level of consciousness
ICU Scoring Systems
Time Frame: between 01.01.2005 and 31.12.2023
Critical illness severity scores (e.g., acute physiology and chronic health Evaluation (APACHE II), simplified acute physiology score (SAPS II), sequential organ failure assessment (SOFA), etc.)
Outcome measure
Time Frame: between 01.01.2005 and 31.12.2023
in-hospital death, survival, survival with neurofunctional alteration, Glasgow Outcome Score, return to neurofunctional premorbid baseline, readmission